Cardiff Oncology
Jon Haines is an Associate Director, Financial Reporting at Cardiff Oncology since July 2019. Prior to that, Jon held roles such as Senior Accountant at Dexcom, Senior Financial Reporting Analyst at PriceSmart, and Senior Accountant at PICO Holdings, Inc. Jon began their career at Ernst & Young as Assurance Staff and also worked as an Accounting Consult at Sayva Solutions. Jon obtained a BS in Journalism from California Polytechnic State University-San Luis Obispo and an MBA in Accountancy from National University.
Cardiff Oncology
Cardiff Oncology is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the greatest medical need. Our goal is to overcome resistance, improve response to treatment and increase overall survival. We are developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics.